Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than chemotherapy alone.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2022-07, Vol.387 (3), p.217-226
Hauptverfasser: Cortes, Javier, Rugo, Hope S., Cescon, David W., Im, Seock-Ah, Yusof, Mastura M., Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H., Perez-Garcia, Jose, Iwata, Hiroji, Masuda, Norikazu, Torregroza Otero, Marco, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhou, Xuan, Karantza, Vassiliki, Pan, Wilbur, Schmid, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Apoptosis
Breast Cancer
Cancer therapies
Carboplatin
Chemotherapy
Confidence intervals
Death
Disease control
Gemcitabine
Hematology
Immunotherapy
Ligands
Lymphocytes
Macrophages
Metastases
Metastasis
Monoclonal antibodies
Nanoparticles
Oncology
Paclitaxel
PD-L1 protein
Pembrolizumab
Placebos
Statistical analysis
Targeted cancer therapy
Treatments in Oncology
Tumor cells
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than chemotherapy alone.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2202809